SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BioLase Technology, Inc. (BLTI)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Karl Drobnic who wrote (541)8/4/1999 12:25:00 PM
From: lizard lick  Read Replies (2) of 706
 
This was issued today
BlueStone Capital Partners Announces Investment Opinion on BLTI
(Business Wire 08/04 10:47:59) Business Editors NOTE TO EDITORS: The following is an investment opinion issued by BlueStone Capital Partners NEW YORK--(BUSINESS WIRE)--Aug. 4, 1999-- BlueStone Capital Partners, L.P. Re-iterates STRONG BUY Rating on BLTI. Senior Analyst, Scott Baily at BlueStone Capital reiterates a STRONG BUY recommendation on Biolase Technology, Inc. (NASDAQ: BLTI- $ 2 25/32) and maintains a 12 month price target of $7-$10 after achieving a number of important milestones in the first half of 1999. Analyst's Summary - BLTI has achieved a number of important milestones during the first half FY99. Combined with the several meaningful announcements recently, and given our expectations for strong results in 2Q FY99 and for the balance of FY99, we remain quite optimistic about BLTI's market leadership opportunities and its growth prospects over the next couple of years. Accordingly, we continue to rate BLTI's stock a STRONG BUY, and our 12 month price target is unchanged at $7-$10. - BLTI recently signed a one year worldwide distribution license for its LazerSmile Tooth Whitening System with Tactica International for an annual minimum quota of 500,000 units. Tactica will pay a royalty per unit to BLTI and has taken over the marketing of LazerSmile, which began in July. We estimate the license can generate $2-$3 million in sales over the next 12 months, of which 90% should be profit. - In June, BLTI received the FDA approval of its Millennium Hydrokinetic laser to dentists for procedures on children under 18 years old. This important FDA approval follows the company's clearance earlier this year of the Millennium for Class II and Class IV, thereby allowing marketing of the laser for all dental classes. - BLTI recently introduced its new MVP-HS Laser Delivery system & several disposable tips for use with its Millennium laser. We believe the MVP-HS system & disposable tips further increases BLTI's technological lead over the competition. BlueStone Capital Partners, L.P. is a full service investment banking and brokerage firm that delivers financial services to emerging growth and medium size companies worldwide. BlueStone Capital assists Clients in maximizing their growth by providing sophisticated investment strategies that are designed to achieve clients' strategic, operating and financial goals. --30--ks/ny* CONTACT: BlueStone Capital Partners, L.P., New York Scott A. Baily Phone (212) 850-0558 KEYWORD: NEW YORK INDUSTRY KEYWORD: Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com S.BW
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext